

1627

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001  
 TIME: 15:21:09

Input Set : A:\Su931011.app  
 Output Set: N:\CRF3\03162001\I482585.raw

ENTERED  
 #8

3 <110> APPLICANT: Hangauer Jr., David G.  
 4 Marsilje, Thomas H.  
 5 Milkiewicz, Karen L.  
 7 <120> TITLE OF INVENTION: A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS  
 9 <130> FILE REFERENCE: 19226/931  
 11 <140> CURRENT APPLICATION NUMBER: 09/482,585  
 12 <141> CURRENT FILING DATE: 2000-01-13  
 14 <150> PRIOR APPLICATION NUMBER: 60/115,643  
 15 <151> PRIOR FILING DATE: 1999-01-13  
 17 <160> NUMBER OF SEQ ID NOS: 6  
 19 <170> SOFTWARE: PatentIn Ver. 2.1  
 21 <210> SEQ ID NO: 1  
 22 <211> LENGTH: 5  
 23 <212> TYPE: PRT  
 24 <213> ORGANISM: Artificial Sequence  
 26 <220> FEATURE:  
 27 <223> OTHER INFORMATION: Description of Artificial Sequence: src substrate  
 28 pentapeptide  
 30 <400> SEQUENCE: 1  
 31 Ile Tyr Gly Glu Phe  
 32 1 5  
 35 <210> SEQ ID NO: 2  
 36 <211> LENGTH: 5  
 37 <212> TYPE: PRT  
 38 <213> ORGANISM: Artificial Sequence  
 40 <220> FEATURE:  
 41 <221> NAME/KEY: PEPTIDE  
 42 <222> LOCATION: (2)  
 43 <223> OTHER INFORMATION: Xaa in position 2 is modified Tyr.  
 45 <220> FEATURE:  
 46 <223> OTHER INFORMATION: Description of Artificial Sequence: src  
 47 pentapeptide scaffold  
 49 <400> SEQUENCE: 2  
 50 Ile Xaa Gly Glu Phe  
 51 1 5  
 54 <210> SEQ ID NO: 3  
 55 <211> LENGTH: 5  
 56 <212> TYPE: PRT  
 57 <213> ORGANISM: Artificial Sequence  
 59 <220> FEATURE:  
 60 <221> NAME/KEY: PEPTIDE  
 61 <222> LOCATION: (4)  
 62 <223> OTHER INFORMATION: Xaa in position 4 is modified Ala.  
 64 <220> FEATURE:  
 65 <223> OTHER INFORMATION: Description of Artificial Sequence: PKA  
 66 pentapeptide scaffold  
 68 <400> SEQUENCE: 3

RECEIVED

MAR 23 2001

TECH CENTER 1600/2900

3/16/01

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001  
TIME: 15:21:09

Input Set : A:\Su931011.app  
Output Set: N:\CRF3\03162001\I482585.raw

OK 69 Arg Arg Gly Xaa Ile  
70 1 5  
73 <210> SEQ ID NO: 4  
74 <211> LENGTH: 5  
75 <212> TYPE: PRT  
76 <213> ORGANISM: Artificial Sequence  
78 <220> FEATURE:  
79 <221> NAME/KEY: PEPTIDE  
80 <222> LOCATION: (4)  
81 <223> OTHER INFORMATION: Xaa in position 4 is Ala or modified Ala.  
83 <220> FEATURE:  
84 <223> OTHER INFORMATION: Description of Artificial Sequence: Boronic  
85 acid-containing PKA inhibitor  
87 <400> SEQUENCE: 4  
OK 88 Arg Arg Gly Xaa Ile  
89 1 5  
92 <210> SEQ ID NO: 5  
93 <211> LENGTH: 7  
94 <212> TYPE: PRT  
95 <213> ORGANISM: Artificial Sequence  
97 <220> FEATURE:  
98 <223> OTHER INFORMATION: Description of Artificial Sequence: Kemptamide  
100 <400> SEQUENCE: 5  
101 Leu Arg Arg Ala Ser Leu Gly  
102 1 5  
105 <210> SEQ ID NO: 6  
106 <211> LENGTH: 7  
107 <212> TYPE: PRT  
108 <213> ORGANISM: Artificial Sequence  
110 <220> FEATURE:  
111 <221> NAME/KEY: MOD\_RES  
112 <222> LOCATION: (5)  
113 <223> OTHER INFORMATION: Xaa in position 5 is ALA; PHOSPHORYLATION  
115 <220> FEATURE:  
116 <223> OTHER INFORMATION: Description of Artificial Sequence: Phosphorylated  
117 Kemptamide  
OK 119 <400> SEQUENCE: 6  
OK 120 Leu Arg Arg Ala Xaa Leu Gly  
121 1 5

VERIFICATION SUMMARY  
PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001  
TIME: 15:21:10

Input Set : A:\Su931011.app  
Output Set: N:\CRF3\03162001\I482585.raw

L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:69 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:120 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6